Medicalgorithmics Cash & Equivalents
The Cash & Short-Term Investments of Medicalgorithmics (MDG.WA) as of Sep 4, 2026 is 5.50 M PLN. In the previous year, Cash & Short-Term Investments was 25.50 M PLN — a change of -78.42% (lower).
Get this data via API
Financial Data API
Cash & Equivalents
5.50 MPLN
YoY
-78.42%
Last updated:
The Medicalgorithmics Cash & Equivalents history
3 Years
10 Years
25 Years
Max
| YEAR | Cash & Equivalents | YoY |
|---|---|---|
| 5.50 MPLN | -78.42% | |
| 25.50 MPLN | -2.54% | |
| 26.17 MPLN | +124.27% | |
| 11.67 MPLN | -27.97% | |
| 16.20 MPLN | +45.26% | |
| 11.15 MPLN | -83.14% | |
| 66.13 MPLN | +79.91% | |
| 36.76 MPLN | -38.43% | |
| 59.70 MPLN | +68.90% | |
| 35.35 MPLN | +44.10% | |
| 24.53 MPLN | — |
Medicalgorithmics Stock analysis
Frequently Asked Questions about Medicalgorithmics stock
Cash & Short-Term Investments of Medicalgorithmics is 5.50 M PLN in 2026.
Cash & Short-Term Investments of Medicalgorithmics changed from 25.50 M PLN to 5.50 M PLN, representing a -78.42% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Cash & Short-Term Investments Medicalgorithmics since 2006 – with annual values, charts, and detailed analysis.
Cash and equivalents represent the most liquid assets on the balance sheet, available for immediate use or short-term obligations.
Cash & Short-Term Investments's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Cash & Short-Term Investments's Medicalgorithmics historically and in real time.
Balance Sheet — Medicalgorithmics
All Key Metrics — Medicalgorithmics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth